![GH Research PLC](/common/images/company/N_GHRS.png)
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1...
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum...
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.58 | 5.23465703971 | 11.08 | 12.197 | 10.94 | 41080 | 11.5012443 | CS |
4 | -0.79 | -6.3453815261 | 12.45 | 12.72 | 10.52 | 40577 | 11.62867581 | CS |
12 | -0.21 | -1.76916596462 | 11.87 | 14.99 | 10.3 | 52993 | 12.16250223 | CS |
26 | 5.75 | 97.2927241963 | 5.91 | 14.99 | 5.5 | 93583 | 9.90726477 | CS |
52 | -1.34 | -10.3076923077 | 13 | 14.99 | 5.05 | 91378 | 9.36261346 | CS |
156 | -5.58 | -32.3665893271 | 17.24 | 30.43 | 5.05 | 83469 | 13.49450593 | CS |
260 | -10.34 | -47 | 22 | 30.43 | 5.05 | 85425 | 13.79129388 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.